Contact
searchSearch
HMP Global
Login

News

News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Phase 3 MonumenTAL-6 Trial Demonstrates Significant Survival Benefit With Dual-Bispecific Immunotherapy in Relapsed or Refractory Multiple Myeloma
07/23/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3...
07/23/2026
Oncology
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
Saurabh Chhabra, MD
Videos
Etentamig Demonstrates Durable Activity Following Prior BCMA Therapy in Multiple Myeloma
06/23/2026
Saurabh Chhabra, MD
Saurabh Chhabra, MD, discusses results from the phase 1b MONVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses results from the phase 1b MONVISO trial showing that the next-generation BCMA×CD3 bispecific antibody etentamig produced durable responses and manageable toxicity in heavily pretreated patients with relapsed or...
Saurabh Chhabra, MD, discusses...
06/23/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
Enrique Ocio, MD, PhD
Videos
DREAMM-9 Final Analysis Shows Strong Efficacy With Belantamab Mafodotin Plus VRd in Newly Diagnosed Multiple Myeloma
06/16/2026
Enrique Ocio, MD, PhD
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM showing that teclistamab produced substantially higher complete response, MRD negativity, and progression-free survival rates than lenalidomide plus dexamethasone in patients...
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM showing that teclistamab produced substantially higher complete response, MRD negativity, and progression-free survival rates than lenalidomide plus dexamethasone in patients...
Omar Nadeem, MD, discusses...
06/15/2026
Oncology
News
Dual-Target CAR T-Cell Therapy OL-101 Shows Deep Responses in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
06/11/2026
Stephanie Holland
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1...
06/11/2026
Oncology

Recent News

News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Outperforms Cisplatin Plus Gemcitabine in Muscle-Invasive Bladder Cancer
08/12/2026
Stephanie Holland
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3...
08/12/2026
Oncology
News
BEGONIA Shows No Added Benefit With Capivasertib or Oleclumab Added to Durvalumab Plus Paclitaxel in Advanced Triple-Negative Breast Cancer
08/12/2026
Emily Estrada
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2...
08/12/2026
Oncology
News
Subcutaneous Pertuzumab Plus Trastuzumab Shows Comparable 4-Year Outcomes to Intravenous Therapy in HER2-Positive Breast Cancer
08/12/2026
Emily Estrada
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase...
08/12/2026
Oncology
News
Foundation AI Model Surpasses Early-Career Dermatologists but Falls Short of Experts in Skin Cancer Diagnosis
08/12/2026
Stephanie Holland
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study...
08/12/2026
Oncology
News
Two Injection Sites Outperformed Single-Site Delivery for Melanoma Peptide Vaccine
08/12/2026
Stephanie Holland
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a...
08/12/2026
Oncology
News
Sonrotoclax Monotherapy Demonstrates Meaningful Activity in Heavily Pretreated Mantle Cell Lymphoma
08/12/2026
Emily Estrada
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study...
08/12/2026
Oncology
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use